^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    1d
    Machine learning-based integration develops a disulfidptosis-related lncRNA signature for improving outcomes in gastric cancer. (PubMed, Artif Cells Nanomed Biotechnol)
    Analyses of functional enrichment and tumour mutation burden highlighted the biological importance of these DRLs, connecting them to critical cancer pathways and immune responses. These discoveries broaden our comprehension of the molecular framework of gastric cancer and bolster the development of tailored treatment plans, highlighting the substantial role of DRLs in clinical prognosis and therapeutic intervention.
    Journal • Tumor mutational burden • Machine learning
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    3d
    Comprehensive analysis of PDE2A: a novel biomarker for prognostic value and immunotherapeutic potential in human cancers. (PubMed, Braz J Med Biol Res)
    Aberrant expression of PDE2A influenced the sensitivity of various antitumor and chemotherapy drugs. This research provided a comprehensive analysis of PDE2A in human cancers, highlighting its potential as both a prognostic marker and an immunotherapy target for future research.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    3d
    Continuous prediction for tumor mutation burden based on transcriptional data in gastrointestinal cancers. (PubMed, BMC Med Inform Decis Mak)
    TMB correlates with clinicopathological parameters in gastrointestinal carcinoma, and patients with high TMB have higher levels of immune infiltration. In addition, the DNN model based on 31 genes predicts TMB of gastrointestinal tumors in a high accuracy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    TMB-H
    3d
    Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=684, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Dec 2024 --> Mar 2025
    Trial primary completion date
    |
    CTNNA1 (Catenin Alpha 1)
    4d
    Prognostic significance of NUAK1 and its association with immune infiltration in stomach adenocarcinoma. (PubMed, Discov Oncol)
    The expression levels of NUAK1 are significantly increased in STAD, and this heightened expression correlates with diminished OS, DSS, and PFI among affected patients. These observations indicate that NUAK1 has the potential to function as a prognostic biomarker for STAD and may represent a viable therapeutic target for intervention in its management.
    Journal
    |
    NUAK1 (NUAK Family Kinase 1)
    4d
    Sintilimab in Combination with Chemotherapy ± Local Treatment for Om-G/GEJ (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Jiangsu Cancer Institute & Hospital
    New P2 trial • Combination therapy • Metastases
    |
    Tyvyt (sintilimab)
    4d
    AndroMETa-GEA: A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=180, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Combination therapy • Metastases
    |
    5-fluorouracil • oxaliplatin • budigalimab (ABBV-181) • leucovorin calcium • telisotuzumab adizutecan (ABBV-400)
    4d
    TRPC6 is a Biomarker for Prognosis and Immunotherapy of Stomach Adenocarcinoma Based on Bioinformatic Analysis and Experimental Validation. (PubMed, Immunotargets Ther)
    TRPC6 expression correlated strongly with immune cell infiltration, immune checkpoint genes, and sensitivity to therapies such as Lapatinib, anti-CTLA4, and anti-PD1 treatments...This study highlights the prognostic significance of TRPC6 in STAD and its potential as a therapeutic target. TRPC6's involvement in immune regulation and cancer cell progression underscores its dual role in STAD pathogenesis and treatment, offering new avenues for targeted therapy development.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TRPC6 (Transient Receptor Potential Cation Channel Subfamily C Member 6)
    |
    lapatinib
    4d
    PREDICT: Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=581, Active, not recruiting, Novomics. Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Dec 2029 | Trial primary completion date: Oct 2026 --> Oct 2029
    Enrollment closed • Trial completion date • Trial primary completion date
    6d
    CONTRAST: BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=18, Terminated, BioInvent International AB | Active, not recruiting --> Terminated; After the completion of phase IA, for business reasons it was decided to terminate the study.
    Trial termination • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Herceptin (trastuzumab) • BI-1607
    6d
    The value of a nomogram based on 18F-FDG PET/CT metabolic parameters and metabolic heterogeneity in predicting distant metastasis in gastric cancer. (PubMed, Jpn J Clin Oncol)
    HI-1 is an independent risk factor for predicting distant metastasis in gastric cancer. A comprehensive prediction model combining HI-1 with the tumor marker CA72-4 can increase the net clinical benefit for patients.
    Journal • FDG PET
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CA 19-9 (Cancer antigen 19-9)
    9d
    Shared and specific competing endogenous RNAs network mining in four digestive system tumors. (PubMed, Comput Struct Biotechnol J)
    Based on RNA correlation analysis, 1, 23, and 2 potential ceRNA regulatory axes were identified in STAD (PVT1/miR-490-3p/HMGA2), LIHC (DLX6-AS1/miR-139-5p/TOP2A, etc.), and COAD (STRCP1 & LINC00488/miR-142-3p/GAB1), respectively. This study advances the understanding of ceRNA networks in digestive cancers, highlighting RNA biomarkers with potential as therapeutic targets for personalized treatment strategies.
    Journal
    |
    TOP2A (DNA topoisomerase 2-alpha) • HMGA2 (High mobility group AT-hook 2) • MIR142 (MicroRNA 142) • COL6A3 (Collagen Type VI Alpha 3 Chain) • MIR139 (MicroRNA 139) • MIR490 (MicroRNA 490) • PVT1 (Pvt1 Oncogene) • CDCA8 (Cell Division Cycle Associated 8) • COL4A1 (Collagen Type IV Alpha 1 Chain) • GAB1 (GRB2 Associated Binding Protein 1)
    9d
    METAGIO: Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Dec 2024
    Enrollment open • Trial initiation date • Metastases
    |
    Opdivo (nivolumab)
    9d
    Multimodal Prehabilitation To Improve The Clinical Outcomes Of Frail Elderly Patients With Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=368, Active, not recruiting, The Affiliated Hospital of Qingdao University | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2023 --> Apr 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    9d
    The HDAC Inhibitor Entinostat Mediates HER2 Downregulation in Gastric Cancer, Providing the Basis for Its Particular Efficacy in HER2 Amplified Tumors and in Combination Therapies. (PubMed, Cancer Res Treat)
    Concomitantly, cells with high basal or treatment-induced HER2 expression showed most profound sensitivities towards HDACi. These findings may thus provide the basis for HDACi treatment as a therapeutic option (1) particularly valuable in HER2-amplified gastric cancer and (2) particularly useful in combination therapies with HER2 inhibitors.
    Journal • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • MIR205 (MicroRNA 205)
    |
    HER-2 amplification • HER-2 expression
    |
    Jingzhuda (entinostat)
    10d
    NCF-1 plays a pivotal role in the survival of adenocarcinoma cells of pancreatic and gastric origins. (PubMed, In Vitro Cell Dev Biol Anim)
    Consequently, the tumor cells highly expressing NCF-1 obtained coincident accumulation of ROS and reduced glutathione (GSH) with expression of glutathione peroxidase 4 (GPX4), a quencher involved in ferroptosis. Unlike the conventional role of ROS as a representative cytotoxic factor, these findings suggest that NCF-1-mediated ROS generation may be required for expansive growth of PDAC and gastric cancers.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4)
    |
    GPX4 expression
    10d
    RAMIRIS: Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy (clinicaltrials.gov)
    P2/3, N=429, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    10d
    NeoART: Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=36, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    New P1/2 trial • Combination therapy
    |
    5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • oxaliplatin
    11d
    KEYNOTE 900: Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer (clinicaltrials.gov)
    P1/2, N=120, Active, not recruiting, MedPacto, Inc. | Trial completion date: Aug 2024 --> Jan 2025
    Trial completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • vactosertib (TEW-7197)
    11d
    Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=14, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2024 --> Dec 2025
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • MSI (Microsatellite instability)
    |
    HER-2 positive • TP53 mutation • MSI-H/dMMR
    |
    FoundationOne® CDx
    |
    irinotecan • berzosertib (M6620)
    11d
    TORCH-G: Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma (clinicaltrials.gov)
    P2, N=68, Recruiting, Fudan University
    New P2 trial • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tyvyt (sintilimab) • capecitabine • oxaliplatin
    12d
    Identification of biomarkers related to Escherichia coli infection for the diagnosis of gastrointestinal tumors applying machine learning methods. (PubMed, Heliyon)
    Moreover, IL16 was high-expressed but PRKCB was low-expressed in STAD cells, and silencing IL16 suppressed the invasion and migration of STAD cells. Overall, we identified and validated 8 robust genes related to E. coli applying bioinformatics and machine learning algorithms, providing theoretical foundations for the relationship between E. coli-related dysbiosis and gastrointestinal tumors.
    Journal • Machine learning
    |
    PRKCB (Protein Kinase C Beta) • IL16 (Interleukin 16)
    12d
    POLESTAR: Chemotherapy and Pembrolizumab, Followed by Pembrolizumab and Olaparib as Firstline Therapy in Her-2 Negative Gastric/GEJ Adenocarcinoma (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase classification: P2a --> P2
    Phase classification
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • capecitabine • oxaliplatin
    12d
    Changing landscapes and increasing relevance of immunotherapy in localized MSI-H gastric adenocarcinoma. (PubMed, Expert Rev Clin Pharmacol)
    No abstract available
    Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    13d
    TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer (clinicaltrials.gov)
    P1/2, N=62, Completed, MedPacto, Inc. | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    paclitaxel • vactosertib (TEW-7197)
    14d
    The role of perioperative chemoimmunotherapy in the treatment of potentially resectable MSI-H gastric adenocarcinoma - a case report. (PubMed, Rozhl Chir)
    This case report supports the potential importance of immunotherapy in the treatment of resectable locally advanced MSI-H gastric cancer, which is currently being evaluated in clinical trials.
    Journal
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    15d
    Circulating Tumor DNA as a Prognostic Biomarker for Recurrence in Patients With Locoregional Esophagogastric Cancers With a Pathologic Complete Response. (PubMed, JCO Precis Oncol)
    Within the subgroup of patients with EGC and favorable pathologic responses (TRG 0-1) after NAT, the presence of postoperative ctDNA identified patients with elevated recurrence risk.
    Retrospective data • Journal • Circulating tumor DNA
    |
    Signatera™
    16d
    A phase II study evaluating safety and efficacy of niraparib in patients with previously treated homologous recombination defective metastatic esophageal/gastroesophageal junction/proximal gastric adenocarcinoma. (PubMed, Front Oncol)
    The most common adverse events seen were anemia, fatigue, and thrombocytopenia. In patients with metastatic EAC, single agent niraparib as second line therapy is not an effective option.
    P2 data • Journal • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ARID1A (AT-rich interaction domain 1A) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • RAD51B (RAD51 Paralog B) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • GEN1 (GEN1 Holliday junction 5' flap endonuclease) • PARP2 (Poly(ADP-Ribose) Polymerase 2)
    |
    FANCA deletion
    |
    Zejula (niraparib)
    16d
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=240, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR • MSH6 expression
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    16d
    Computer-aided analysis reveals metallothionein-positive cancer-associated fibroblasts promote angiogenesis in gastric adenocarcinoma. (PubMed, Discov Oncol)
    The M2d-mtCAF axis may play an important role in GC angiogenesis. This study not only enhances our understanding of the TME heterogeneity in GC but also sheds light on the interaction between CAFs and tumor-associated macrophages (TAMs) in tumor angiogenesis.
    Journal
    |
    MT1X (Metallothionein 1X)
    |
    VEGFA overexpression • VEGFA expression
    17d
    CARMEN-GC01: Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Sanofi | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date • Combination therapy • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Cyramza (ramucirumab) • tusamitamab ravtansine (SAR408701)
    19d
    Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment. (PubMed, Heliyon)
    CD73 could be used to predict the prognosis of patients with several cancers. The potential functional mechanism of CD73 involved in cancer progress may not only dependent on its immunomodulatory effects.
    Journal • Tumor mutational burden • BRCA Biomarker • Pan tumor
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • BRCA (Breast cancer early onset) • CD73 (5'-Nucleotidase Ecto) • CD4 (CD4 Molecule) • NT5E (5'-Nucleotidase Ecto)
    |
    CD73 expression
    24d
    HSP90 Inhibitor AUY922 Suppresses Tumor Growth and Modulates Immune Response through YAP-TEAD Pathway Inhibition in Gastric Cancer. (PubMed, Cancer Lett)
    Our findings highlighted the suggestion of targeting HSP90 in GAC therapy via down-regulating YAP1/TEAD signaling. Additionally, our results suggest that AUY922's ability to reshape the GAC TME favoring the host sets the stage for a clinical trial that combines HSP90 and checkpoint inhibition, where HSP90 could serve as a biomarker for patient selection.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • YAP1 (Yes associated protein 1) • GZMB (Granzyme B)
    |
    luminespib (AUY922)
    26d
    Screening high-risk individuals for primary gastric adenocarcinoma: evaluating progression-free survival probability score in the presence and absence of Rictor expression after gastrectomy. (PubMed, Front Oncol)
    This study presents the first risk stratification for Rictor status in gastric adenocarcinoma. Our model identifies low-risk patients who may not require additional postoperative treatment, while high-risk patients should consider targeted therapies that specifically target Rictor-positive indicators.
    Journal
    |
    MSH2 (MutS Homolog 2)
    27d
    BGB-A317-ZW25-101: Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab (clinicaltrials.gov)
    P1/2, N=71, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Oct 2024
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    docetaxel • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Ziihera (zanidatamab-hrii)
    1m
    Relationship between [18F]FDG PET/CT findings and claudin 18.2 expression in metastatic gastric cancer. (PubMed, Eur Radiol)
    Question The study resolves the clinical issue of determining the correlation between [18F]FDG PET/CT imaging and claudin 18.2 expression in metastatic gastric cancer. Findings Claudin 18.2-positive metastatic gastric cancers exhibit relatively lower [18F]FDG uptake than negative ones. The SUVmax of 10.9 moderately predicts claudin 18.2 expression. Clinical relevance [18F]FDG PET/CT imaging could be a noninvasive way to predict claudin 18.2 status in metastatic gastric cancer, helping to improve personalized treatment plans.
    Journal • FDG PET • Metastases
    |
    CLDN18 (Claudin 18)
    |
    CLDN18.2 expression • CLDN1 positive
    1m
    GRAMMY: InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer (clinicaltrials.gov)
    P=N/A, N=250, Recruiting, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Active, not recruiting --> Recruiting | Trial completion date: Sep 2023 --> May 2027 | Trial primary completion date: Sep 2023 --> May 2027
    Enrollment open • Trial completion date • Trial primary completion date
    1m
    Novel Fused Pyrimidines as Potent Cyclin-Dependent Kinases Inhibitor for Gastric Adenocarcinoma: Combined In Vitro, In Silico Anticancer Studies. (PubMed, Chem Biol Drug Des)
    Among the synthesised compounds, 2-(pyridin-3-yl)-4-(pyridin-3-yl)-5,6-dihydrobenzo[h]quinazoline 8b and 4-(2-(pyridin-3-yl)-5,6 dihydrobenzo[h]quinazolin-4-yl) phenol 5g exhibited potent anticancer activity compared to (R)-Roscovitine...Furthermore, the efficacy of compound 5g was validated through an in vitro CDK2/cyclin A2 enzyme inhibition assay. Interestingly, the observed CDK2 inhibitory activity showed a good correlation with the corresponding value for the antiproliferative activity of the tested compounds.
    Preclinical • Journal
    |
    CCNA2 (Cyclin A2)
    |
    seliciclib (CYC202)
    1m
    Pan-cancer analysis of CLDN18.2 shed new insights on the targeted therapy of upper gastrointestinal tract cancers. (PubMed, Front Pharmacol)
    Additionally, low CLDN18.2 expression was linked to favorable prognosis. Our study reveals the potential value of CLDN18.2 for tumor prognosis and targeted therapy in various cancers, especially upper gastrointestinal tract cancers.
    Journal • Pan tumor
    |
    CLDN18 (Claudin 18) • CD4 (CD4 Molecule)
    |
    CLDN18.2 expression • CLDN18.2 overexpression • CLDN18.2 underexpression
    1m
    Navigating the complex landscape of crawling-type gastric adenocarcinomas: Insights and implications for clinical practice. (PubMed, World J Gastrointest Oncol)
    Moreover, a heightened awareness urging the adoption of advanced diagnostic techniques and collaborative approaches is necessary among clinicians and researchers. We aim to contribute to the ongoing discourse in gastrointestinal oncology, emphasizing the importance of recognizing and addressing the complexities associated with rare cancer subtypes such as CRA.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TP53 (Tumor protein P53) • RHOA (Ras homolog family member A)
    |
    TP53 mutation • HER-2 amplification
    1m
    Hepatoid adenocarcinoma of the stomach: discrimination from conventional gastric adenocarcinoma with a computed tomography-based radiomics nomogram. (PubMed, J Gastrointest Oncol)
    The nomogram model yielded excellent accuracy for identifying HAS, achieving an AUC of 0.970 (95% CI: 0.923-0.992) in the training cohort and 0.905 (95% CI: 0.796-0.968) in the test cohort. Radiomics analysis offers promise for differentiating HAS from CGA, and the CT-based radiomics nomogram is likely to have significant clinical implications on HAS distinction.
    Journal
    |
    AFP (Alpha-fetoprotein)
    1m
    The role of FOXK2-FBXO32 in breast cancer tumorigenesis: Insights into ribosome-associated pathways. (PubMed, Thorac Cancer)
    Our research provides insights into the significance of FOXK2 in cancer and indicates its potential as both a prognostic indicator and target for treatment. The ribosome-associated pathways involving FOXK2 and FBXO32 could be pivotal in the advancement of tumors, offering possible avenues for targeted and individualized immunotherapy approaches. Additional research is required to completely understand the mechanisms that are responsible for the participation of FOXK2 and its subsequent gene FBXO32 in cancer, as well as to explore the possible advantages of focusing on FOXK2 for cancer treatment.
    Journal • IO biomarker
    |
    FBXO32 (F-Box Protein 32)